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1. Summary
The transition between the inactive T-state (apoenzyme) and
active R-state (effector bound enzyme) of Trypanosoma cruzi
pyruvate kinase (PYK) is accompanied by a symmetrical 8◦ rigid
body rocking motion of the A- and C-domain cores in each
of the four subunits, coupled with the formation of additional
salt bridges across two of the four subunit interfaces. These salt
bridges provide increased tetramer stability correlated with an
enhanced specificity constant (kcat/S0.5). A detailed kinetic and
structural comparison between the potential drug target PYKs
from the pathogenic protists T. cruzi, T. brucei and Leishmania
mexicana shows that their allosteric mechanism is conserved. By
contrast, a structural comparison of trypanosomatid PYKs with
the evolutionarily divergent PYKs of humans and of bacteria
shows that they have adopted different allosteric strategies.
The underlying principle in each case is to maximize (kcat/S0.5)
by stabilizing and rigidifying the tetramer in an active R-state
conformation. However, bacterial and mammalian PYKs have
evolved alternative ways of locking the tetramers together. In
contrast to the divergent allosteric mechanisms, the PYK active
sites are highly conserved across species. Selective disruption of
the varied allosteric mechanisms may therefore provide a useful
approach for the design of species-specific inhibitors.
2. Background
Pyruvate kinase (PYK, EC 2.7.1.40) catalyses the final step
in glycolysis, namely the transfer of a phospho group from
phosphoenolpyruvate (PEP) to ADP to form pyruvate and ATP.
2014 The Authors. Published by the Royal Society under the terms of the Creative Commons
Attribution License http://creativecommons.org/licenses/by/4.0/, which permits unrestricted















Figure 1. Structure of PYK and identification of regulatory binding sites. (a) A monomer of the TcPYK-F26BP-OX-Mg complex (shown
as cartoon, PDB ID: 4ks0) superposed onto the human M1PYK-Pro structure (shown as ribbon, PDB ID: 3n25 [1]). The TcPYK monomer is
coloured to highlight domains; N (blue, residues 1–18), A (yellow, residues 19–89 and 188–358), B (red, residues 90–187) and C (pink,
residues 359–499). Space-filling representations are used to show oxalate, F26BP and proline (Pro), as well as Mg and K. The inserted
loop (Ser100-Asp-Pro-Ile-Leu-Tyr105) from human M1PYK is shown in black and is conserved in human M2PYK. (b) A representative PYK
tetramer (TcPYK PDB ID: 4ks0 is shown here) highlighting the (i) active, (ii) effector and (iii) amino acid binding sites. The active site has
bound oxalate, ATP, Mg and K; the effector site bound F26BP; and the attenuating site bound proline. The pivot region about which the
protomers rotate is shown in black. The large (A–A) and small (C–C) interfaces betweenmonomers are shown as vertical and horizontal
dashed lines, respectively.
PYK exists primarily as a homotetramer with subunits of 50–60 kDa (depending on species), each of
which is composed of four domains: the N-terminal (not present in bacteria), A-, B- and C-domains
(figure 1a). An additional C’-domain is also found in PYKs from Geobacillus stearothermophilis [2] (figure 2)
and Staphylococcus aureus [6]. The active site is nestled between the A- and B-domains and is located
approximately 39 Å from the effector site which is located in the C-domain. In the tetramer, adjacent
C-domains form the C–C or ‘small’ interface, and neighbouring A-domains form the A–A or ‘large’
interface. The B-domain contributes a mobile lid at one end of the (α/β)8-barrelled A-domain and
modulates access to the active site.
The overall tetrameric structure of PYK is highly conserved across distant phylogenetic groups;
however, strategies for the regulation of PYK activity vary substantially between species [2,7–11]. Three
distinct ligand-binding sites with affinities for a range of small molecules have been identified in PYK
tetramers and are particularly well characterized in mammals, trypanosomatids, yeast and bacteria
(figure 1b). These sites are designated here as (i) the active site, (ii) the effector site, and (iii) the amino
acid binding site. Most PYKs display cooperative binding of the substrate PEP at the active site, with
characteristic sigmoid binding curves and Hill coefficients > 1 (e.g. table 1). In this way, glycolytic flux
can be augmented in response to the presence of elevated levels of PEP.
Modulation of PYK activity by activators and inhibitors which bind to the effector site is well
characterized (table 1). Fructose 1,6-bisphosphate (F16BP) is the allosteric activator of three of the four
mammalian isoenzymes: RPYK (erythrocyte), LPYK (liver) and M2PYK (embryonic or tumour). The
fourth isoenzyme is the constitutively active M1PYK found in skeletal muscle. The activity of M1PYK
can also be attenuated by the binding of amino acids such as proline or phenylalanine at the amino
acid binding site [9,23]. PYK from Escherichia coli is also activated by F16BP, but PYK from Geobacillus
stearothermophilus is allosterically activated by AMP or ribose 5-phosphate (R5P) [8] which probably bind
at a position corresponding to the effector site [2]. PYK from baker’s yeast Saccharomyces cerevisiae is also
activated by F16BP [17] (table 1). Interestingly, PYKs from plants and archaea appear to be unresponsive
to effectors such as F16BP or R5P [24,25]. There are currently no structural data for plant or archaeal PYKs.
The ‘TriTryp’ group of trypanosomatid parasites are responsible for diseases, including sleeping
sickness (caused by Trypanosoma brucei), leishmaniasis (caused by various species of Leishmania)




Figure 2. Sequence alignment of pyruvate kinases from trypanosomatids, humans, yeast and bacteria. The sequence alignment was
performed using the program Clustal Omega at the European Bioinformatics Institute [3,4]. Domain boundaries are indicated by
vertical arrows in domain-specific colours: N-terminal domain (blue), A-domain (yellow), B-domain (red) and C-domain (pink). The
extra C-terminal domain (C’-domain) which potentially plays a role in tetramer stabilization is shaded in yellow. The conservation of
the residues is indicated by shading from black (identical in eight sequences) to grey (conserved in five, six or seven) to white (low
or no conservation). Residue numbers corresponding to each PYK are listed after the sequences. Residue numbers corresponding to
trypanosomatid PYKs are also listed above the sequences. The methionine residues at the N-termini correspond to the start codons and
do not necessarily occur in the mature proteins. In trypanosomatid PYKs, the amino acids involved in divalent metal binding (oxalate-
coordinating metal, Mg-1 site) (green asterisk), potassium metal binding (purple asterisk), oxalate binding (blue asterisk), nucleotide
binding (red asterisk) and effector F26BP binding (pink asterisk) are indicated by asterisks. Residues 263–269 of the smallα-helix Aα6′
which are involved in allosteric regulation and in binding divalent metal and oxalate are indicated by a dashed box (cyan). The effector
loop residues are indicated by a pink dashed box. The F16BP binding residues in human M2PYK are shown by red boxes. The residues
involved in stacking interactions to stabilize the effector loop of human M2PYK are indicated by triangles in red. The inserted loop
(Ser100-Asp-Pro-Ile-Leu-Tyr105) from human M2PYK/M1PYK is shaded in green. The figure was generated using the program Aline [5].
Tc, Trypanosoma cruzi (UniProtKB: Q4D9Z4); Tb, Trypanosoma brucei (UniProtKB: P30615); Lm, Leishmaniamexicana (UniProtKB: Q27686);
Hs, Homo sapiens (UniProtKB: P14618); Sc, Saccharomyces cerevisiae (baker’s yeast) (UniProtKB: P00549); Ec, Escherichia coli (UniProtKB:










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































[26]. Trypanosomatid PYKs are allosterically activated by micromolar concentrations of fructose 2,6-
bisphosphate (F26BP), instead of F16BP which is effective only at millimolar concentrations [27] (table 1).
The X-ray structures of PYK from L. mexicana [10] and T. brucei [12] have been determined. Here, the first
apoenzyme and R-state structures for T. cruzi PYK (TcPYK) are presented, thereby providing a detailed
structural and enzymatic comparison for each of the ‘TriTryp’ family members. Analysis of the R- and
T-state PYK structures from trypanosomatids, mammals and bacteria also provides an explanation of the
evolutionary divergence of allosteric regulation.
3. Material and methods
3.1. Materials
ADP, PEP, oxalate (OX), F16BP, F26BP, lactate dehydrogenase (LDH; rabbit muscle), polyethylene glycol
(PEG) 8000, antibiotics and buffers were obtained from Sigma-Aldrich. NADH and EDTA-free protease
inhibitor mixture tablets were from Roche, glycerol was from BDH Prolabo, IPTG was from Melford
and salts were from Fisher Scientific. Restriction enzymes, vector and E. coli competent cells were from
Novagen.
N-terminal His6-tagged TcPYK was prepared as described previously [28]. Briefly, the expression of
His6-tagged TcPYK was achieved by the T7lac promoter-driven system in E. coli BL21 (DE3) cells after
adding IPTG to a final concentration of 1 mM. Pure protein was obtained by immobilized metal ion
affinity chromatography (IMAC) followed by gel-filtration chromatography. N-terminally His6-tagged
human pyruvate kinases (M1PYK and M2PYK) were expressed in E. coli BL21(DE3) cells and purified
using IMAC and gel-filtration chromatography as described previously [16].
3.2. Enzyme activity assay and kinetics study
The activity and kinetics of TcPYK were determined as described for T. brucei PYK (TbPYK) previously
[12]. Briefly, the activity of TcPYK was measured by following the decrease in NADH absorbance at
339 nm, where one activity unit is defined as the conversion of 1µmol substrate per minute under
standard conditions. The assay was performed at 298 K in 100µl reaction mixtures containing 50 mM
triethanolamine (TEA) buffer, pH 7.2, 50 mM KCl, 10 mM MgCl2, 10% glycerol, 0.5 mM NADH and 5µg
(3.2 U) of LDH. The turnover number (kcat) of TcPYK was calculated by the enzyme specific activity
divided by the subunit molar mass of 56769.1 (g mol−1). Enzyme kinetics with regard to ADP was
studied at saturating concentrations of PEP (10 mM) and variable concentrations of ADP (from 0 to
2.5 mM). Enzyme kinetics with regard to PEP was studied at saturating concentrations of ADP (2.5 mM)
and variable concentrations of PEP (from 0 to 10 mM) in the presence or the absence of 1µM F26BP,
or in the presence or the absence of 4.5 mM F16BP. Enzyme kinetics with regard to the effector F26BP
was studied at 2.5 mM ADP, 0.4 mM PEP and variable concentrations of F26BP (from 0 to 1µM), while
enzyme kinetics with regard to the effector F16BP was studied at 2.5 mM ADP, 0.7 mM PEP and variable
concentrations of F16BP (from 0 to 4.5 mM). The Michaelis–Menten equation or its extended equations
were fitted to the experimental data to calculate the values of the kinetic parameters. The parameter S0.5
is used instead of Km when the substrate binding shows cooperativity. The parameter Ka0.5 refers to the
concentration of activator at which half the maximal activation is observed.
3.3. Thermal shift assay (differential scanning fluorimetry)
Melting temperature (Tm) was determined by a thermal shift assay using a fluorescence method as
described for TbPYK previously [12]. For TcPYK and TbPYK, the assay buffer contained 50 mM TEA, pH
7.2, 100 mM KCl, 10 mM MgCl2, 10× SYPRO Orange dye (the dye was supplied by Invitrogen (catalogue
number S6650) at 5000× concentration in DMSO, and diluted in assay buffer for use), 4µM TcPYK or
TbPYK, in the presence or the absence of 1µM F26BP.
3.4. Dynamic light scattering
The Tm values for human M2PYK and human M1PYK were also determined by monitoring changes in
light scattering with increasing temperature. Five microlitres of human M2PYK or human M1PYK (10 mg




Table 2. Data collection parameters, refinement and Ramachandran plot statistics. Values in parentheses are for the highest
resolution shell.
Apo-TcPYK TcPYK-F26BP-OX-Mg
data collection and processing
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
space group C2 I422
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
unit-cell parameters (Å,◦) a = 113.78, b = 121.42, c = 97.16 a = 173.77, b = 173.77, c = 211.86
α = γ = 90.00,β = 115.73 α = β = γ = 90.00
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
solvent content (%) 53 65
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
wavelength (Å) 0.98 0.98
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
resolution (Å) 43.77 − 2.50 55.90 − 2.80
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
no. of reflections 252 349 (31 324) 553 645 (58 315)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
no. of unique reflections 38 483 (5416) 39 095 (5770)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Wilson B-factor (Å2) 37.4 69.7
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Rmerge (%) 9.0 (25.7) 12.1 (51.5)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
〈I/σ I〉 13.7 (5.8) 20.1 (3.7)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Rmeas (%)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
within I + /I− 10.5 (30.6) 12.6 (54.3)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
all I+ and I− 10.4 (30.2) 12.6 (54.3)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Rp.i.m.(%)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
within I + /I− 5.5 (16.4) 3.3 (17.0)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
all I+ and I− 3.9 (11.9) 3.3 (17.0)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
completeness (%) 93.7 (90.5) 100.0 (100.0)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
multiplicity 6.6 (5.8) 13.8 (10.1)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
refinement statistics
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
monomers in asymmetric unit 2 2
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
no. of reflections 36 536 38 066
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Rwork/Rfree 16.06/22.28 17.39/21.63
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
no. of non-H atoms
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
protein 7610 7417
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ligands 12 52
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
metal ions 2 4
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
water 451 254
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
average B-factors (Å2)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
overall 30.39 54.01
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
protein 30.53 54.59
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
protein (excluding B-domains) 26.45 46.75
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ligands 44.58 42.19
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
metal ions 46.96 46.84
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
water 27.86 39.60








. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
bond lengths (Å) 0.01 0.01
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
bond angles (◦) 1.02 1.03
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Ramachandran plot
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
favoured (%) 95.9 94.7
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
allowed (%) 99.9 99.7
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
no. of outliers 1a 3b
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
aThe outlier residue is Thr296 in chain B, a key active site residue that is commonly found in this configuration in PYK structures.
bThe outlier residues are Ile134 in chain A which is modelled in the poor electron density, and Thr296 in both chains.
(50 mM stocks prepared in 100 mM TEA buffer, pH 7.2), the final volume was then adjusted to 50µl using
dilution buffer (10 mM TEA (pH 7.2) and 2% glycerol).
A Zetasizer Auto Plate Sampler was used to determine the Z-average molecular ‘size’ in terms of
the hydrodynamic diameter in solution. Changes in the Z-average or particle diameter with increased
temperature (293–353 K in increments of 1 K) were monitored in automated mode (typically requiring
a measurement duration of 150 s; 13 acquisitions were determined for each run and repeated in
triplicate). The resulting data were then analysed using the manufacturer’s software provided (Malvern
Instruments Ltd, Malvern, UK).
3.5. Crystallization, data collection and structure determination
Purified TcPYK aliquots (30 mg ml−1) were diluted to 15 mg ml−1 using a buffer containing 50 mM TEA
(pH 7.2) or supplemented with 3.5 mM ATP, 3.5µM F26BP and 3.5 mM oxalate. Single crystals of TcPYK
or TcPYK complexed with F26BP, Mg2+ and oxalate (there was no evidence of ATP from the crystal
structure) were obtained at 277 K by vapour diffusion using the hanging drop technique. The drops
were formed by mixing 1.5µl of protein solution with 1.5µl of a well solution composed of 8–18% PEG
8000, 20 mM TEA buffer (pH 7.2), 50 mM MgCl2, 100 mM KCl and 10–20% glycerol. The drops were
equilibrated against a reservoir filled with 0.5 ml of well solution.
Prior to data collection, crystals were equilibrated for 14 h over a well solution composed of 8–18%
PEG 8000 (2% above the crystallization conditions), 20 mM TEA buffer (pH 7.2), 50 mM MgCl2, 100 mM
KCl and 25% glycerol, which eliminated the appearance of ice rings. Intensity data were collected at
the Diamond synchrotron radiation facility in Oxfordshire, UK on beamline I04 (TcPYK) or I03 (TcPYK-
F26BP-OX-Mg) to a resolution of 2.50 Å (TcPYK), or 2.80 Å (TcPYK-F26BP-OX-Mg). All datasets were
obtained from a single crystal flash frozen in liquid nitrogen at 100 K. The TcPYK structures were solved
as described previously [28].
Superpositions of PYK structures were performed using both PyMOL [29] and CCP4 superpose
[30,31]. CCP4 superpose was also used to calculate the allosteric rigid body rotations of TcPYK from the
superposition of T- and R-state tetramers (AC cores) as described previously [10]. Both RMS difference
numbers and rotation matrices were calculated in the superposition process.
4. Results and discussion
4.1. TcPYK and TbPYK have similar kinetic parameters
Values of TcPYK kinetic parameters were determined for PEP in the presence and absence of both the
trypanosomatid PYK allosteric activator F26BP and the more general activator F16BP at 298 K and
are summarized in table 1, together with the parameters previously reported for TbPYK [12]. In the
absence of F26BP, the S0.5 values for PEP were 1.23 mM and 1.03 mM for TcPYK and TbPYK, respectively,
both exhibiting positive cooperativity (h> 1) and similar specificity constants (kcat/S0.5 values of 137
and 141 s−1 mM−1, respectively). In the presence of F26BP, the S0.5 value for PEP decreased ninefold
and the specificity constant increased 11-fold (average kcat/S0.5 value of 1514 mM−1 s−1) for both TcPYK




Figure 3. Close-up of the active site of TcPYK-F26BP-OX-Mg showing themetal coordination and stabilization of the smallα-helix Aα6′
by oxalate binding. The polypeptide chain is shown as a cartoon. Ligands and interacting residues are shown as sticks. Residue Phe213
which potentially favours the binding of oxalate in the same pose as the substrate PEP is also shown in stick format. Chain B of the
protein is coloured yellow and chain D is blue. The divalent metal ion Mg2+ and monovalent ion K+ are shown as a green sphere and
a purple sphere, respectively. The Fo–Fc electron densities for Mg2+ and K+ are shown as grey meshes contoured at 3.0 σ and 4.0 σ ,
respectively. Water molecules are shown as red spheres. Potential interatomic interactions are indicated by purple dashed lines and the
relevant distances are given in ångströms. Detailed metal coordination is shown in the electronic supplementary material, figure S1.
general effector F16BP decreased the S0.5 value for PEP fourfold and increased the specificity constant
fivefold, although these effects were observed only at concentrations over 1000 times higher than that
of F26BP. There are no data available for the intracellular concentrations of F16BP and F26BP in T. cruzi;
however, in vivo concentrations for F16BP and F26BP have been determined for the bloodstream form of
T. brucei as approximately 600µM for F16BP and approximately 10µM for F26BP (calculated from data
in [32] and assuming 175 mg total cellular protein per millilitre total cellular volume [33]). In T. cruzi,
there is an interestingly large difference in the Ka0.5 values for F26BP (0.03µM) and F16BP (1239µM)
(table 1). The corresponding Ka0.5 values for T. brucei are 0.01 and 50µM. Based on the suggested relative
cellular concentrations of the FBPs and their PYK affinities, it is not out of the question that F16BP may
also contribute to PYK activation in trypanosomatids.
4.2. Sequence identity explains different effector recognition
The TcPYK amino acid sequence is 81% identical to TbPYK and 76% to LmPYK (electronic supplementary
material, table S1), with residues involved in substrate and effector binding conserved (figure 2). This
high degree of sequence conservation between trypanosomatids is reflected in their similar kinetic
parameter values (table 1). TcPYK and the F16BP-regulated human M2PYK are only 47% identical
(electronic supplementary material, table S1), although the residues involved in substrate binding exhibit
100% sequence conservation (figure 2). The side chains involved in effector binding are much more
variable and show only 57% sequence identity.
4.3. T- to R-state transition: a common pivot region
Both T- and R-state TcPYK X-ray crystal structures were obtained under near identical (pH 7.2) conditions
(see table 2 for data collection and refinement statistics). In the R-state structure (TcPYK-F26BP-OX-Mg),
the active and effector sites are occupied by Mg2+-oxalate and F26BP, respectively (figures 3 and 4).
In the T-state structure of TcPYK (apo-TcPYK), the effector loop (Ala482-Gly488) is disordered in the




Figure 4. Close-up of the effector site of TcPYK (TcPYK-F26BP-OX-Mg, chain A) showing the binding mode of the activator F26BP. The
protein is shown as a cartoon, except the residues involved in F26BP binding which are shown as sticks. The F26BP molecule is shown
as sticks with an unbiased Fo–Fc election density map contoured at 4.0 σ (grey). Water molecules are shown as red spheres. Possible
interactions involved in F26BP binding are indicated by dashed lines in yellow. The ordered effector loop (Ala482-Gly488) is also indicated.
A schematic drawing showing the interatomic distances of the interactions is shown in the electronic supplementary material, figure S2.
transition involves a rigid body rotation of subunits (excluding B-domains; AC cores; figure 5a–c),
whereby the subunits pivot 8◦ (electronic supplementary material, table S2) around a region (residues
430–433) located at the base of the αβ barrel of domain A (figure 1b). In a similar way, LmPYK experiences
a rigid body rotation of its AC cores during the transition between T- and R-states [10]. A superposition
of the TcPYK and LmPYK AC cores gave a Cα RMS fit of 0.7 and 0.6 Å for the T- and R-states, respectively.
By contrast, superposition of the AC core of active R-state TcPYK with the equivalent human M2PYK
structure (PDB ID: 3bjf) gave an average RMS fit of 2.3 Å. Besides the effector site, the major difference
between these structures is an extended loop (inserted loop) between the C-terminal portion of helix
Aα2 and the N-terminal portion of strand Aβ3 (figure 1a). This extended loop which is also conserved
in human M1PYK corresponds to six additional amino acid residues (Ser100-Asp-Pro-Ile-Leu-Tyr105)
(figure 2) and seems to play a central role in regulating M2PYK activity. Mutation of Ile103 of human
M2PYK to a tyrosine causes the formation of a monomeric form of M2PYK known as cytosolic thyroid
hormone-binding protein p58 [34]. In addition, phosphorylation of Tyr105 has been shown to inhibit
M2PYK activity [35]. Moreover, this region also comprises part of a known amino acid binding site in
M1PYK (figure 1a). The pivot point is located close to the amino acid binding site and suggests that
ligands binding to this site may affect the rocking motion of the AC cores and as a result modulate
enzyme activity.
4.4. Effector loop conformation is responsible for allosteric control
The hydrogen bond interactions between F26BP and trypanosomatid PYKs are remarkably similar to
those found in the F16BP–M2PYK complex (figure 6) which explains why TbPYK, TcPYK and LmPYK
are able to bind both effectors (table 1). However, higher concentrations (at least 1000-fold) of F16BP
over the concentration of F26BP are required to induce a (weaker) allosteric response compared with
F26BP. In the TcPYK-F26BP-OX-Mg structure, the 2′- and 6′-phospho groups of the F26BP molecule form
a series of hydrogen bonds similar to those of F16BP in the human M2PYK-F16BP-OX-Mg structure
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Figure 5. The T- to R-state allosteric transition results in the formation of inter-chain interactions and increased thermal stability.
Schematic of the (a) T- and (c) R-state TcPYK crystal structures. (b) Superposition of the T-state AC core structure onto the R-state AC core
structure (all B-domains have been removed). The 8◦ rigid body rotations of the AC cores occurring during the T- to R-state transition have
been indicated using arrows to show the direction of movement. (d) Thermal unfolding of TcPYK and (e) TbPYK in the absence and the
presence of the effector molecule F26BP. (f ) Cartoon representations of the T- and (g) R-state TcPYK structures; (h,i) after rotation by 90◦.
Amino acids involved in inter-chain interactions are shown as spheres. The effector loops are disordered in the T-state but becomeordered
upon effector binding resulting in formation of salt bridges across the C–C interface.
PYKs (replaced by a threonine in the M2PYK-OX-F16BP structure) stacks with the furanose ring of F26BP
positioning the 3′-OH and 4′-OH groups for hydrogen bond formation via the backbone nitrogen of
Ala482 and the carbonyl of Leu390, respectively. The 1′-CH2OH group of F26BP forms a hydrogen bond
via the backbone nitrogen of Gly488 (figure 6a), stabilizing the effector loop conformation.
By contrast, the effector loop of the M2PYK-F16BP-OX-Mg structure is stabilized by hydrogen bonds
from 3′-OH and 4′-OH groups with the carbonyls of Arg516 and Gly518 and the backbone nitrogen
of Phe521 and Gly514 (figure 6b). The conformation of the effector loop is further stabilized through
a series of stacking interactions (Trp482, Pro517, Arg516, Trp515 and Phe521). These subtly different
effector interactions in the two structures result in different conformations of effector loop: in the TcPYK
structure the 1′-CH2OH group prevents the effector loop from folding up around F26BP and stabilizes
the loop in a position that favours the formation of an inter-chain salt bridge (Asp483. . .Arg494) across the
C–C interface (figure 5g,i), an interaction essential for allosteric control [10]. Instead of forming additional
salt bridges, the binding of F16BP to human M2PYK stabilizes a lysine-mediated ‘peg-in-hole’ connection
across the C–C interface [16].
4.5. Increased thermal stability correlates with increased kcat/S0.5
The stabilizing effects of PYK cofactors, inhibitors and metals were analysed using thermal shift
assays. An increase in melting temperature (Tm) reflects an increase in structural order and reduced
conformational flexibility. Addition of the effector molecule (F26BP) to apo-TcPYK or apo-TbPYK
increased the melting temperature by 2 K and 8 K, respectively (figure 5d,e). The addition of F16BP to
M2PYK also showed a dramatic increase in the Tm from 315 to 325 K (figure 7a), close to the Tm of the
non-allosterically regulated M1PYK, for which all complexes had identical Tm values of 325 K (figure 7b).








Figure 6. Stereo pictures of the F26BP and F16BP effector binding sites of trypanosomatid and human PYK. (a) A close-up view of the
effector site of the TcPYK-F26BP-OX-Mg structure showing the binding mode of F26BP (pink carbon atoms). The polypeptide chain is
shown in cartoon format, with residues involved in F26BP binding shown as sticks. For comparison, the position of F16BP (green carbon
atoms) from the human M2PYK-F16BP-OX-Mg structure (PDB ID: 3bjf) [36] is also shown. The two structures were superimposed by
fitting corresponding Cα atoms from the effector sites of both PYK structures. Effector binding stabilizes the effector loop (Ala482-Gly488)
and the interaction of the 1′-CH2OH group (blue circle) of F26BP additionally holds the effector loop in a conformation that favours the
formation of the allosteric salt bridge (Arg494. . .Asp483). (b) A close-up view of the effector site of the M2PYK-F16BP-OX-Mg structure
showing the binding mode of F16BP. In contrast to the TcPYK-F26BP-OX-Mg structure, the effector loop in M2PYK-F16BP-OX-Mg moves
further from the C–C interface, essentially wrapping around the effectormolecule. For comparison, the position of F26BP from the TcPYK-
F26BP-OX-Mg structure is also shown; the two structures were superimposed using selected corresponding Cα atoms from the effector
site. Interestingly, the 1′-CH2OH group belonging to F26BP clashes (less than 2 Å; purple circle) with the human effector loop position.
Green dashed lines highlight stacking interactions.
4.6. Changes in the C–C interface account for increased enzyme stability and kcat/S0.5
Previous site-directed mutational studies on LmPYK have shown that the increased stability is the result
of a series of stabilizing salt bridges formed across the C–C tetramer interface [10]. These interactions
are also observed in the TcPYK-F26BP-OX-Mg structure (figure 5i), indicating a similar mechanism
of regulation. Upon addition of effector an increase in Tm is observed for all trypanosomatid PYKs
correlating with a 10- to 14-fold increase in kcat/S0.5, clearly demonstrating the relationship between
rigidity and activity.
The addition of effector molecule to apo-M2PYK dramatically increased the Tm from 315 to 325 K
(figure 7a) with a concomitant 16-fold increase in kcat/S0.5 (table 1). A recent analysis of the oligomeric
state of M2PYK provided a novel mechanism for tetrameric stabilization, whereby M2PYK exists in a
monomer–tetramer equilibrium [16,37], and binding of the allosteric effector F16BP stabilizes the peg-
in-hole connection across the C–C interface of the tetramer to shift this equilibrium to a predominantly
tetrameric state (figure 8e,f ). Addition of F16BP reduces thermal vibration along the C–C interface (apo-










































Figure7. Stabilizationof thehumanM2PYK tetramerbybindingof F16BP. (a) Thermal shift assay results for humanM2PYKand (b) human
M1PYK complexes monitored by dynamic light scattering. Assays were performed in 20 mM TEA (pH 7.2) and 10% glycerol. Samples were
as follows: M2_APO, M2PYK in buffer only; M2_metals, M2PYK in buffer containing 50 mM MgCl2 and 100 mM KCl; M2_metals_F16,
M2PYK in buffer containing metals and 1 mM F16BP; M2_metals_PEP, M2PYK in buffer containing 50 mM MgCl2, 100 mM KCl and 1 mM
PEP; M2_metals_F16_PEP, M2PYK in buffer containing 50 mM MgCl2, 100 mM KCl, 1 mM PEP and 1 mM F16BP; M2_metals_PHOSPHY,
M2PYK in buffer containing 50 mM MgCl2, 100 mM KCl and 1 mM phosphotyrosine; M2_metals_5mMPO4, M2PYK in buffer containing
50 mM MgCl2, 100 mM KCl and 5 mM phosphate. Corresponding samples are shown for M1PYK in (b). The Tm for M2PYK is 315 K in the
absence of F16BP, shifting by 10 K to 325 K in the presence, similar to that of (unligated) M1PYK (325 K).






























Figure 8. The evolution of allosteric control of PYK. Schematic of the effector induced T- to R-state allosteric transition. This transition
results in the formation of molecular bridges between chains creating a more rigid, highly active R-state conformer. (a) The ‘inactive’
Geobacillus stearothermophilus PYK (GsPYK) T-state tetramer (PDB ID: 2E28). An extra domain (residues 474–587) corresponding to the
effector loop in the trypanosomatid structures is shown in green. This domainwas predicted to have a hinge typemovement (HingeProt)
[38] and itsmovement probablymimics the trypanosomatid effector loop, formingmolecular bridges between chains (as shown in b) and
the thermally stable highly active R-state tetramer observed in solution. (c) In trypanosomatid PYKs F26BP binding stabilizes the effector
loop, resulting in the formation of a series of stabilizing salt bridge interactions across the C–C interface (as shown in d), generating
the highly stable (Tm = 2–8 K) R-state tetramer. (e) The ‘inactive’ form of the human M2PYK is monomeric (Tm = 315 K) in solution
shifting to tetrameric (Tm = 325 K) upon F16BP binding. Addition of F16BP reduces thermal vibration along the C–C interface and locks





the active tetramer conformation. We suggest that the 16-fold increase in specificity constant results
from stabilization of the tetramer and promotes conformational states which favour substrate binding
(8.6-fold decrease in S0.5) and/or catalytic activity and/or product release. In addition, restriction in its
conformational states reduces the ensemble of inactive conformational states thereby favouring substrate
binding. The activity of M1PYK also correlates with tetrameric stability as the X-ray structure (PDB:
3SRF) shows a tighter peg-in-hole binding across the C–C interface compared with M2PYK which locks
the enzyme in a constitutively active tetramer conformation (figure 7b).
Tetrameric stabilization by means of effector binding has also been observed for the bacterial PYK
from G. stearothermophilis (GsPYK). GsPYK exists as a tetramer and is regulated by the allosteric activator
ribose 5-phosphate (R5P) [8]. Lovell et al. have shown that the addition of the effector molecule results
in a highly thermostable GsPYK conformation, demonstrating the increased rigidity of effector bound
complexes. Determination of the crystal structure of GsPYK [2] revealed that the C-terminal extension
forms an extra domain (domain C’) in place of the trypanosomatid PYK effector loop (figure 8a). This
domain is predicted to have a hinge-like movement, possibly interacting with adjacent monomers and
forming stabilizing bridges across the C–C interface (figure 8b), similar to those observed for the salt
bridge effector loops of trypanosomatid PYKs (figure 8d).
4.7. Evolution of allosteric control mechanisms
Trypanosomatid PYKs are allosterically regulated by the binding of F26BP, human M2PYK (and many
other PYKs) by F16BP, and certain bacterial PYKs by AMP or monophosphorylated sugars. While the
regulatory molecules and molecular mechanisms may vary between species the underlying principle of
tetrameric stabilization in response to effector binding is conserved.
Three types of allosteric mechanisms are found in evolutionarily divergent species of PYK (figure 8).
(i) Bacterial PYKs as exemplified by the GsPYK tetramer (figure 8a,b) are stabilized by the rotation of a
series of additional domains (domain C’) which bridge across the C–C interface thereby stabilizing the
tetramer. (ii) Trypanosomatid PYKs (figure 8c,d) possess simple loops (effector loops) which again form
a series of bridges across the C–C interface enhancing tetramer stability. (iii) Human M2PYK (figure 8e,f )
has evolved in a different direction whereby it is able to dissociate into inactive monomers, and the
active tetramer is formed and stabilized in response to effector binding. The allosteric characteristics
observed for all PYKs suggest that effector bound PYKs have higher thermal stability and greater
enzymic activity. Selective disruption of these allosteric mechanisms may provide new and specific drug
targets which avoid the problem of developing selective inhibitors against similar active sites. Such
inhibitors/activators could be used to tackle trypanosomiasis, cancer (M2PYK [39]), anaemia (RPYK
[40]) and bacterial infection (methicillin-resistant Staphylococcus aureus PYK [6]).
Data accessibility. Protein crystal structures deposited with the PDB: TcPYK apoenzyme, 4krz; TcPYK-F26BP-OX-Mg,
4ks0.
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